Press english

2005-2015: a decade innovating for your health

The years between 2005 and 2015 have witnessed the birth and growth of Bionaturis Group. Since its foundation as spin-off of the University of Cadiz until the start of their international expansion a few months ago, the company has enjoyed the successes and has learned from the mistakes but certainly it has put innovation at the service of science with the clear goal of providing a global access to a high-performance health.

Since its creation back in 2005 by the PhD in Sciences, Victor Infante, today CEO and chairman, there are several landmarks that stand in the path of this biopharmaceutical company born in the province of Cadiz, such as the beginning of the development of the  FLYLIFE platform in 2008, floating on the alternative stock market (MAB) in 2012, new outstanding contracts with multinational institutions for the development of vaccines and other medicines, and more recently, the beginning of international expansion with the acquisition of other companies and the implementation in other continents.

From having a single employee in 2005, the entrepreneur himself, to employ directly a staff of 30 people with an average age of 36 years of which 45% are PhDs. Every year the company has increased the value created for its shareholders and for society in general, with a steady growth in sales figures, number of jobs, customers, suppliers, partners, etc.. Currently the company has reached a market capitalization value of around 30 million €.

There are many people who in one way or another have participated in these first ten years of life and to all and each one of them we want to share this tenth anniversary. In our timeline you can recall the major milestones achieved to date by Bionaturis. […]

March 17th, 2015|Blog english, Press english|Comments Off|

Mr Robert Jones visits FLYLIFE manufacturing platform at Bionaturis Group

The Regional Commercial Counselor at the Embassy of the United States in Spain, Mr Robert Jones, has just visited Bionaturis Group in Jerez accompained by the Senior International Commercial Specialist, Helen Crowley. The President of the Camara de Comercio de Jerez, Javier Sánchez Rojas; and its General Manager, Juan Núñez; among others guests, have also participated in the visit.

Mr Jones has personally learned  Bionaturis Group’ mission and vision, which bets on applying innovation, talent and technology to offer a more equal access to cutting-edge medicines all over the world. Mr Jones –who has participated in a conference about USA ‘A market in eternal growth’, organized by the Camara de Comercio de Jerez- has visited the biological medicines production plant including  its innovative manufacturing platform named FLYLIFE. He expressed  great interest in how Bionaturis Group is able to manufacture high number of doses of the most effective medicines currently available in the market in a fast and affordable way.

Bionaturis Group is nowadays developing its international expansion, which includes physical presence in other continents and the acquisition of other companies in the Industry in order to increase its services coverage and portfolio.

February 6th, 2015|Blog english, Press english|Comments Off|

Vote for Bionaturis Group at European Business Awards

Bionaturis Group has been nominee for the international European Business Awards, organized by RSM. After getting the certification of National Champion, Bionaturis Group is one of the 27 European companies shortlisted within the category ‘The BP Target Neutral Growth Strategy of the Year Award’.

In this new stage of the competition, the general public can participate voting the presentation videos of the candidates on the web http://www.businessawardseurope.com/ . The process is very simple and the deadline for voting is next 24th, February. You can watch and vote for Bionaturis Group video here.

January 19th, 2015|Blog english, Press english|Comments Off|

Bionaturis Group, winner at the Small and Mid-Cap Awards

Bionaturis Group has been recently honored with the first prize at the Small and Mid-Cap Awards, within the ‘Rising Star’ category. These awards are organized by the European Commission’s Directorate-General for Enterprise and Industry (DG ENTR) in collaboration with EuropeanIssuers and FESE (Federation of European Securities Exchanges). Awards sponsored by NASDAQ, EURONEXT, BDO, DEUTSCHE BÖRSE GROUP, IRIS STOCK EXCHANGE, and OSLO BØRS.

Bionaturis Group CEO and founder, Victor Infante, collected the award during a ceremony hold in Brussels.

December 10th, 2014|Blog english, Hechos Relevantes, Press english|Comments Off|

Bionaturis takes part in the annual meeting of the European project Targetfish

PhD Ana de las Heras, the person in charge of the Targetfish project within Bionaturis Group, attended the annual meeting of this European consortium intended to develop new vaccines for aquaculture.

During the meeting, held in the Universidad Autonoma of Barcelona, the activities of each of the 30 partners from 13 different countries were reviewed. From Bionaturis Group, Ana de las Heras explained the advances in new vaccine formulations for trout and seabass, being developed along other partners in Targetfish.

Moreover, Targetfish is working on the research of preventive treatments for other species such as salmon, seabream and turbot. All of them the most relevant species in the aquaculture industry in Europe.

A project for excellence

Led by PhD Geert Wiegertjes (Department of Animal Sciences, Cell Biology & Immunology group from Wageningen UR), Targetfish brings together leading European research groups that are experts on the fish immune system and enterprises from the Biotech and Veterinary sectors. This project, to be concluded in the fall of 2017, is funded by the European Commission 7th Framework programme.

If you want to know more about Targetfish, please click here.

November 5th, 2014|Blog english, congress, Press english|Comments Off|

“BioSpain 2014 has confirmed our position in the sector”

The delegates of Bionaturis Group at BioSpain 2014 has confirmed its positioning in the sector. In just three days they hold 40 one-to-one meetings to bolster existing business relationships and starting new collaborations for the next future.

“The quality and fruitfully meetings hold there demonstrate that we are in the right path. There are more and more multinational companies and institutions that are interested in working with us to move forward innovative solutions to the market. The unique features of the FLYLIFE platform to develop biological drugs and the versatility of the zebrafish animal model to optimize the drug discovery process were the hot topics during the meetings. A perfect blend between innovation and international expansion with a newborn effective presence in China makes us a perfect partner of choice”, the delegates have stated.

BBD BioPhenix presentation

Besides taking part as expositor within the Bionaturis Group stand (booth B9), BBD BioPhenix  gave a speech as part of the workshop titled “Key Enabling Technologies Applied to BIO”. In particular, R&D Manager, Arantza Muriana, delivered the conference “Key Enabling Technologies, fundamental part of zebrafish based screenings”.

In total, more than 3,000 partnering meetings has been hold in this forum and the presence of national and international investors has gained special relevance this edition. Check the highlights at #BioSpain2014.

 

 

September 30th, 2014|Blog english, Press english|Comments Off|

Bionaturis holds the Technical Comitee of SNC-Integra project

Bionaturis has recently held the III Technical Executive Committee of the Consortium SNC_Integra, led by Laboratorios Rovi and taking part Bionaturis and other companies such as Canvax, GMV, VivaCell, Vivia Allosterics and Vivia Biotech. The project is funded by the Centre for Industrial Technological Development (CDTI, in Spanish), by the public-private cooperation program for R&D initiatives, FEDER-INNTERCONECTA.

The goal of this project is obtaining, in a completely safe and efficient way, new drugs to treat pathologies related to the Central Nervous System. Its main aim is to improve the patients’ quality of life and reduce the required health care.

After the meeting, the attendees could visit FLYLIFE’s facilities.

Treatment for the Gaucher disease

As it is published on the market, the main task of Bionaturis in this consortium is to develop an oral FLYLIFE version of the human recombinant glucocerebrosidase as ERT (Enzyme Replacement Therapy) for Gaucher disease type I. The goal is to improve the patients’ life, who nowadays are receiving the enzyme by intravenous infusion.

With the FLYLIFE version of this human enzyme, Bionaturis pretends to have a superior formulation to be stable until its absorption in the intestine facilitating membrane crossing and targeting the organs where the enzyme is required -liver, spleen, bone marrow, and Central Nervous System. As it was announced in the latest annual report, Bionaturis has developed the production protocol of the own version of the enzyme, called Bentoglucerasa (BNT001), with a yield that guarantees its industrial production. Bionaturis has shown its ‘in vitro’ activity and started a preclinical research in cell and mice models.

If you want to know more details about SNC_Integra, please click here.

 

By FLYLIFE vaccines against diseases as Ebola could be manufactured

Bionaturis (ticker BNT) scientists have analyzed the situation on protection against this disease which, unfortunately, is on the news in recent weeks. Based on the antigenic capacity in murine models of the glycoprotein of the Ebola virus capside (S1090, Journal of Infection Diseases, 2011:204 – Suppl. 3-, Tsuda et to the), Bionaturis team could develop a recombinant vaccine in its FLYLIFE system. Bionaturis would follow similar strategies already successfully used for other vaccine developments based on this type of protein within the company.

According to Dr Juan Jose Infante, CSO of the company, “there are data showing that, properly presented, this antigen may confer protection against the Ebola virus in healthy patients. Bionaturis has the track record and necessary knowledge in recombinant antigen presentation to pursue a high rate of success. On the other hand, unlike other options being considered, such as the use of an attenuated virus to carry this protein, a recombinant vaccine strategy would be much more safer during the production and handeling and would have less uncertainty regarding safety in healthy vaccinated humans. In the event of a successful development using FLYLIFE, thanks to its features, Bionaturis could release batches of million doses within four weeks upon order receipt. Dealing with any emergency the population at risk would be protected, guaranteeing total safety for the rest”.

Bionaturis scientists estimate that within a maximum of 24 months it would be viable to deliver experimental doses of a hipothetical  new vaccine, with proven safety and efficacy tested in animal models and ready to be tested in primates and humans, or to be used in cases of emergency as the occurred in the last month. Bionaturis´team is evaluating the possibilities of development of this vaccine along with its commercial and technological […]

August 19th, 2014|Blog english, Press english|Comments Off|

Bionaturis’ vaccine against Visceral Canine Leishmaniasis, preventive and therapeutic

Bionaturis continues the development of BNT005, a vaccine against Visceral Canine Leishmaniasis, a disease that affects dogs and is spread in Mediterranean countries as Spain, being registered an increasing rate of zoonosis (when an animal disease infects humans) lately. The visceral one is the most serious type of Leishmaniasis and it can be lethal if it is not treated well. It is caused by the parasites Leishmania and transmitted by the bite of the phlebotomine sandfly that acts as a vector.

Nowadays there is not any vaccine already in the market to prevent or treat humans against this disease, being its development a priority of the World Health Organization (WHO). The current treatment with antiparasitics has undesirable side effects and it causes the outbreak of resistance phenomena in the parasite. However, for dogs there are few options approved in Europe and LATAM, that claim themselves as prophylactic but not therapeutic.

Dogs among rabbits are the main reservoir of Leishmaniasis. Because of that, its control is essential to avoid the spread of this disease in humans (zoonosis). “A vaccine against canine Leishmaniasis has a double goal. Firstly, in the animals, which will be protected or can be treated against a disease that is fatal in a high percentage of cases. And, secondly, in humans, who will have less possibilities of suffering the disease if their pets do not have the parasite or they have them under control”, Bionaturis’ CSO, Juan Jose Infante, has stated.

Tests in rodents and Beagle dogs

Infante has also stood out that “the difference between BNT005 by Bionaturis and others vaccine attempts to fight this disease is that the preliminary results obtained and published in the last annual management report show that Bionaturis’ vaccine induces […]

August 12th, 2014|Blog english, Press english|Comments Off|

Andoni Cruz, BBD BioPhenix: “This new stage with Bionaturis is a big opportunity to grow in international markets”

Bionaturis acquired last May the company BBD BioPhenix, a leader in state-of-the-art screening systems for drug discovery. Its general manager, Andoni Cruz, highlights the main values of the company and the challenges they are facing from now on after this movement with Bionaturis.

-What is the outstanding value of BBD?

BBD is a Contract Research Organisation (CRO) that uses the zebra fish as animal model for drug screening. Comparing  to other alternatives using this model we can talk about eight years of cumulative experience. One of our main features that makes us different from the competition is the orientation to tailor-made assays to fulfill the specific requirements of our customers, from different sectors such as the pharmaceutical, petrochemical, agrochemical, cosmetics and nutraceutical industries, always needed of customized solutions. Moreover, BBD is one of the first zebra fish CRO that is working under GLPs (Good Laboratory Practices) and our track record working with multinational companies is a great presentation card.

-How are you facing this new period with Bionaturis? In what values are both coinciding?

This new time ahead of us is an opportunity to grow in international markets with the solid financial and commercial support of Bionaturis. The access to the Chinese and LATAM markets, using Bionaturis current position will mean a turning point in the growing expectations of the company.

On the other hand, I stand out the high level of synergies that both companies have in their business philosophy and vision, with the recruitment and retention of talent and innovation as their rock-solid bases.  Both companies share the goal of seeking solutions to optimize the drug discovery and production processes that will make easier to people to access cutting-edge drugs with the final common goal of democratizing […]

August 11th, 2014|Blog english, Press english|Comments Off|

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR